Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy DOI Creative Commons

Sheng‐Liang Cheng,

H.T. Lee,

Chung‐Pin Li

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(43), P. 29439 - 29456

Published: Oct. 15, 2024

The stimulator of interferon genes (STING) pathway is crucial for tumor immunity, leading to the exploration STING agonists as potential immunotherapy adjuvants. However, their clinical application faces obstacles including poor pharmacokinetics, transient activation, and an immunosuppressive microenvironment (TME). Addressing these limitations, our study aims develop injectable silk fibroin hydrogel-based in situ vaccine. It incorporates a nanoscale agonist, immunogenic cell death (ICD) inducer, immunomodulator ensure controlled sustained release. cGAMP nanoparticles (cGAMPnps) with core–shell structure optimal delivery dendritic cells (DCs), thereby activating fostering DC maturation. ICD-associated damage-associated molecular patterns amplify prolong activation via enhanced type I IFN other inflammatory pathways, along delayed degradation STING. Furthermore, STING-driven vascular normalization by cGAMPnps ICD, conjunction immunomodulators like antiprogrammed protein 1 antibody (anti-PD-1 Ab) or OX40 ligand (OX40L), effectively remodels TME. This gel vaccine, when used independently surgery neoadjuvant/adjuvant immunotherapy, enhances CD8+ T-cell suppressing progression recurrence across various immunologically cold models. revolutionizes cancer offering substantial promise improving outcomes broad spectrum malignancies.

Language: Английский

Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy DOI Open Access
Da Qian, Jialu Li, Mingyao Huang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 162, P. 114685 - 114685

Published: April 12, 2023

Breast cancer (BC) is the most common in women worldwide. Although substantial progress has been made diagnosis and treatment of breast cancer, efficacy side effects traditional methods are still unsatisfactory. In recent years, immunotherapy including tumor vaccine achieved great success BC. Dendritic cells (DCs) multifunctional antigen-presenting that play an important role initiation regulation innate adaptive immune responses. Numerous studies have shown DC-based treatments might a potential effect on Among them, clinical study DC BC demonstrated considerable anti-tumor effect, some vaccines entered stage trials. this review, we summarize immunomodulatory related mechanisms as well trials to propose possible challenges new development directions.

Language: Английский

Citations

24
Cascade Carrier‐Free Nanoparticles Forming In Situ Nanovaccines for Synergistic Photothermal‐Immunotherapy of Cancer DOI
Chenlu Huang, Hanyong Wang, Xinyu Yang

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(29)

Published: April 5, 2024

Abstract Rapid advances in nanotechnology have made it possible to combine photothermal therapy (PTT) with immunotherapy, enabling activate an situ vaccine effect. However, this effect is severely impeded by low antigen presentation level and highly suppressive tumor immune microenvironment (immune “cold” tumors). To overcome the obstacles, multifunctional carrier‐free nanoparticles (FCDP‐NPs) assembled from Fe 2+ , toll‐like receptor 9 agonist (CpG), cationic lipid (DOTAP) agent polydopamine are developed. After intratumoral injection, FCDP‐NPs carrying positive charge exposed under laser irradiation, which can capture tumor‐associated antigens (TAAs) generated upon post‐PTT form nanovaccines (FCD‐NPs@TAAs). The further promote cross‐presentation of TAAs, stimulate adaptive responses, shape “hot” tumors. As a result, improve survival rates elicit durable memory that remarkedly prevents metastasis, illustrating useful platform for PTT synergized immunotherapy.

Language: Английский

Citations

15
Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy DOI Creative Commons
Chunbao Zang, Yu Tian, Yujing Tang

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Sept. 30, 2024

Language: Английский

Citations

12
Biodegradable pyroptosis inducer with multienzyme-mimic activity kicks up reactive oxygen species storm for sensitizing immunotherapy DOI
Junrong Wang,

Luying Qiao,

Guo‐Qing Zhu

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 370, P. 438 - 452

Published: May 6, 2024

Language: Английский

Citations

11
Extracellular Matrix Scaffold‐Assisted Tumor Vaccines Induce Tumor Regression and Long‐Term Immune Memory DOI
Sanjay Pal, Rohan Chaudhari, Iris Baurceanu

et al.

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(15)

Published: Feb. 2, 2024

Abstract Injectable scaffold delivery is a strategy to enhance the efficacy of cancer vaccine immunotherapy. The choice biomaterial crucial, impacting both release kinetics and immune stimulation via host response. Extracellular matrix (ECM) scaffolds prepared from decellularized tissues facilitate pro‐healing inflammatory response that promotes local surveillance. Here, an ECM scaffold‐assisted therapeutic maintains microenvironment consistent with tissue reconstruction engineered. Several immune‐stimulating adjuvants are screened develop formulated small intestinal submucosa (SIS) co‐delivery. It found STING pathway agonist cyclic di‐AMP most effectively induces cytotoxic immunity in vaccine, without compromising key interleukin 4 (IL‐4) mediated pathways associated healing. enhances efficacy, curing 50–75% established E.G‐7OVA lymphoma tumors mice, while none cured soluble vaccine. SIS‐ECM vaccination prolonged antigen exposure dependent on CD8 + T cells generates long‐term antigen‐specific memory for at least 10 months post‐vaccination. This study shows promising vehicle being orthogonal characteristics hallmarks.

Language: Английский

Citations

9
Recent Developments in CaCO3 Nano-Drug Delivery Systems: Advancing Biomedicine in Tumor Diagnosis and Treatment DOI Creative Commons

Chenteng Lin,

Muhammad Akhtar, Yingjie Li

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(2), P. 275 - 275

Published: Feb. 15, 2024

Calcium carbonate (CaCO3), a natural common inorganic material with good biocompatibility, low toxicity, pH sensitivity, and cost, has widespread use in the pharmaceutical chemical industries. In recent years, an increasing number of CaCO3-based nano-drug delivery systems have been developed. CaCO3 as drug carrier utilization efficient Ca2+ CO2 donor played critical role tumor diagnosis treatment explored depth breadth. Starting from system, this paper systematically reviews preparation nanoparticles mechanisms therapeutic effects internal external environments summarizes latest advances application therapy. view biocompatibility vivo mechanisms, they are expected to become advancing biomedicine field treatment.

Language: Английский

Citations

9
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines DOI Open Access
Yuanyuan Li, Yuxing Xu,

Wenwen Su

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2025, Volume and Issue: 184, P. 117897 - 117897

Published: Feb. 7, 2025

Language: Английский

Citations

1
Recent advancements of hydrogels in immunotherapy: Breast cancer treatment DOI
Jagannath Mondal, Kushal Chakraborty,

Edwin J. Bunggulawa

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 372, P. 1 - 30

Published: June 13, 2024

Language: Английский

Citations

7
Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer DOI Creative Commons

Gayathri Kandasamy,

Yugeshwaran Karuppasamy,

Uma Maheswari Krishnan

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(2), P. 458 - 458

Published: Feb. 16, 2023

Despite advancements in the development of anticancer medications and therapies, cancer still has greatest fatality rate due to a dismal prognosis. Traditional therapies include chemotherapy, radiotherapy, targeted therapy. The conventional treatments have number shortcomings, such as lack selectivity, non-specific cytotoxicity, suboptimal drug delivery tumour locations, multi-drug resistance, which results less potent/ineffective therapeutic outcome. Cancer immunotherapy is an emerging promising strategy elicit pronounced immune response against cancer. Immunotherapy stimulates system with cancer-specific antigens or checkpoint inhibitors overcome suppressive microenvironment kill cells. However, antigen activation need circumvent issues pertaining short lifetimes effect times, well adverse effects associated off-targeting, suboptimal, hyperactivation system. Additional challenges posed by are immunogenicity inhibition effector T evolution nanotechnology recent years paved way for improving treatment efficacy facilitating site-specific sustained moiety robust response. amenability nanoparticles towards surface functionalization tuneable physicochemical properties, size, shape, surfaces charge been successfully harnessed immunotherapy, combination therapy, In this review, we summarized made choosing different nanomaterial combinations their modifications enable interaction molecular cellular targets efficient immunotherapy. This review also highlights trends strategies be used independently, combination, destruction cells, prevent metastasis recurrence.

Language: Английский

Citations

16
Recent advances in hydrogels for preventing tumor recurrence DOI
Qiuhui Qian, Jie Song, Chen Chen

et al.

Biomaterials Science, Journal Year: 2023, Volume and Issue: 11(8), P. 2678 - 2692

Published: Jan. 1, 2023

The common skeletons and formulations of hydrogels for tumor recurrence are summarized. review emphasizes unique properties postoperative prevention provides a broader insight into clinical transformation hydrogels.

Language: Английский

Citations

15